Bristol-myers Squibb Company · NYSE:BMY
Bristol-myers Squibb — Q2 2026 Earnings Presentation
16 slides from Bristol-myers Squibb's earnings presentation, Jul 30, 2026
Slide 1: Q2 2026 Results
Q2 2026 Results July 30, 2026 Not for Product Promotional Use
Slide 2: Forward Looking Statements and Non-GAAP Financial Information
Forward Looking Statements and Non-GAAP Financial Information This presentation (as well as the oral statements made with respect to information contained financial measures are provided as supplemental information and are presented because herein) contains statements about Bristol-Myers Squibb Comp
Slide 3: Q2 2026 Results - Chris Boerner, PhD
Q2 2026 Results Chris Boerner, PhD Board Chair and Chief Executive Officer 3
Slide 4: Q2 2026 Performance
Q2 2026 Performance Growth Portfolio Revenues Key Milestones1 $ in billions +15%; +14% Ex-FX* ASCO Data highlighted the breadth of innovation across our oncology franchise $6.6 $7.6 CELMoDs: advancing towards commercialization Iberdomide PDUFA: August 17, 2026 Mezigdomide PDUFA: May 13, 2027 Q2 2025
Slide 5: Significant data expected in 2026…and beyond
Significant data expected in 2026…and beyond* NME registrational data LCM pivotal data Key next wave early-stage data 2026 2026 2026 • Admilparant IPF (ALOFT-IPF) • Sotyktu SLE (POETYK SLE-1 & 2) • BCMAxGPRC5D dual-targeting CAR T RRMM • Arlo-cel 4L+ MM (QUINTESSENTIAL) • Golcadomide 1L FL (GOLSEEK-
Slide 6: Rewiring how we operate
Rewiring how we operate* AI-Powered Execution Operating Discipline Financial Flexibility Expanding AI to help teams Company-wide savings Invest in growth drivers, move faster and operate through strategic productivity pursue strategic business more efficiently, further initiative, combined with deve
Slide 7: Q2 2026 Results - David Elkins
Q2 2026 Results David Elkins Executive Vice President and Chief Financial Officer 7
Slide 8: Growth Portfolio continues to drive revenues
Growth Portfolio continues to drive revenues $ in billions Growth Portfolio $13.0 $12.3 5.4 5.7 Other Growth Brands1 +15% YoY $7.6 $6.6 +14% Legacy Portfolio Ex-FX* Q2 2025 Q2 2026 Other Mature Brands *See “Forward-Looking Statements and Non-GAAP Financial Information”; 1. Other Growth Brands: Abecm
Slide 9: Q2 2026 Oncology product summary
Q2 2026 Oncology product summary Global Net Sales1 Opdivo $M YoY % Ex-FX* % • Remains an important revenue contributor to the Growth Portfolio and continues to deliver value to 2 $2,485 (3%) (4%) patients Qvantig $769 +6% +5% • Continued global growth is driven by meaningful convenience to patients
Slide 10: Q2 2026 Hematology product summary
Q2 2026 Hematology product summary Global Net Sales1 Reblozyl $M YoY % Ex-FX* % • Growth driven by continued global demand across MDS-associated anemia, with the predominant share $735 +29% +29% in 1L $484 +41% +41% Breyanzi 2 • Continued strong demand as the leading CD19 directed $425 (49%) (49%) C
Slide 11: Q2 2026 Cardiovascular & Immunology product summary
Q2 2026 Cardiovascular & Immunology product summary Global Net Sales (Cardiovascular) Camzyos $M YoY % Ex-FX* % • Continued strong global demand and market penetration in oHCM $4,481 +22% +21% • Strong launch momentum outside the U.S. $416 +60% +59% Eliquis • Continued U.S. demand growth and market
Slide 12: Q2 2026 Neuroscience product summary
Q2 2026 Neuroscience product summary Global Net Sales Cobenfy $M YoY % Ex-FX* % • Steady growth trajectory expected near term • Improving patient experience through prescriber $169 +12% +12% education emphasizing optimized dose utilization $63 +81% +81% *See “Forward-Looking Statements and Non-GAAP
Slide 13: Q2 2026 Financial Performance
Q2 2026 Financial Performance GAAP US GAAP Non-GAAP Non-GAAP * $ in billions, except EPS Q2 2026 Q2 2025 Q2 2026 Q2 2025 Total Revenues, net 13.0 12.3 13.0 12.3 Gross Margin %1 71.3% 72.5% 71.4% 72.6% Operating Expenses2 4.8 4.3 4.1 4.0 Acquired IPR&D - 1.5 - 1.5 Amortization of Acquired Intangibles
Slide 14: Strategic approach to Capital Allocation
Strategic approach to Capital Allocation Cash flow from Operations $B Business • Pursue opportunities and partnerships to diversify Development portfolio & strengthen long-term outlook $6.3 $3.9 Balance Sheet • Strong balance sheet affords financial flexibility $3.4 Strength • Maintain strong invest
Slide 15: 2026 Guidance
2026 Guidance* Non-GAAP1 Key Highlights April (Prior) July (Updated) • FY revenue vs. prior guidance reflects strong first half results and our current projections for the year: Total FY Revenues ~$46.0 - $47.5B ~$49.0 - $50.0B (Reported & Ex-FX) • Continued Growth Portfolio strength Gross Margin %
Slide 16: Q2 2026 Results Q&A
Q2 2026 Results Q&A Chris Boerner, PhD David Elkins Adam Lenkowsky Cristian Massacesi, MD Board Chair, Executive VP, Executive VP, Executive VP, Chief Executive Officer Chief Financial Officer Chief Commercialization Chief Medical Officer, Officer Global Drug Development
Bristol-Myers Squibb Company — Q2 2026 Earnings Presentation on 6ix